CPI-455

• Description:

  CPI-455 is a specific, pan-KDM5 inhibitor with an IC50 of 10 nM for KDM5A. CPI-455 mediates KDM5 inhibition, elevates global levels of H3K4me3, and decreases the number of drug-tolerant persister cancer cells in multiple cancer cell line models treated with standard chemotherapy or targeted agents[1].

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  Histone Demethylase

• Type:

  Reference compound

• Related Pathways:

  Epigenetics

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/CPI-455.html

• Concentration:

  10mM

• Purity:

  98.95

• Solubility:

  DMSO : 31.25 mg/mL (ultrasonic)

• Smiles:

  N#CC1=C2NC(C3=CC=CC=C3)=C(C(C)C)C(N2N=C1)=O

• Molecular Formula:

  C16H14N4O

• Molecular Weight:

  278.31

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Vinogradova M, et al. An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells. Nat Chem Biol. 2016 Jul;12 (7) :531-8.|[2]Benjamin R. Leadem. NOVEL HISTONE DEMETHYLASE INHIBITORS SYNERGISTICALLY|[3]Xiang Yuan, et al. Blockade of Immune-Checkpoint B7-H4 and Lysine Demethylase 5B in Esophageal Squamous Cell Carcinoma Confers Protective Immunity against P. gingivalis Infection. Cancer Immunol Res. 2019 Sep;7 (9) :1440-1456.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  KDM5

• CAS Number:

  [1628208-23-0]